Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition
Small · 2024
DOI: 10.1002/smll.202311507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Bai-Xue Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology the NMPA and State Key Laboratory of R…. Hauptthemen laut MEDLINE: Photochemotherapy, B7-H1 Antigen, Immunotherapy, Cyclin-Dependent Kinase 5. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
The immunosuppressive characteristics and acquired immune resistance can restrain the therapy‐initiated anti‐tumor immunity. In this work, an antibody free programmed death receptor ligand 1 (PD‐L1) downregulator (designated as CeSe) is fabricated to boost photodynamic activated immunotherapy through cyclin‐dependent kinase 5 (CDK5) inhibition. Among which, FDA approved photosensitizer of chlorin e6 (Ce6) and preclinical available CDK5 inhibitor of seliciclib (Se) are utilized to prepare the nanomedicine of CeSe through self‐assembly technique without drug excipient. Nanoscale CeSe exhibits an increased stability and drug delivery efficiency, contributing to intracellular production of reactive oxygen species (ROS) for robust photodynamic therapy (PDT). The PDT of CeSe can not only suppress the primary tumor growth, but also induce the immunogenic cell death (ICD) to release tumor associated antigens. More importantly, the CDK5 inhibition by CeSe can downregulate PD‐L1 to re‐activate the systemic anti‐tumor immunity by decreasing the tumor immune escape and therapy‐induced acquired immune resistance. This work provides an antibody free strategy to activate systemic immune response for metastatic tumor treatment, which may accelerate the development of translational nanomedicine with sophisticated mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences, Guangzhou M…
ORCID-Profile: Shi-Ying Li
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Key Areas of Colleges and Universities in Guangdong Province
- National Basic Research Program of China
Zitieren
APA
Yu, B. X., Liu, Y. B., Chen, X. Y., Zhang, W., Cen, Y., Yan, M. Y., Liu, Q. Q., & Li, S. Y. (2024). Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition. Small. https://doi.org/10.1002/smll.202311507
Vancouver
Yu BX, Liu YB, Chen XY, Zhang W, Cen Y, Yan MY, et al. Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition. Small. 2024. doi:10.1002/smll.202311507
BibTeX
@article{Yu2024,
author = {Yu, Bai-Xue and Liu, Yi-Bin and Chen, Xia-Yun and Zhang, Wei and Cen, Yi and Yan, Meng-Yi and Liu, Qian-Qian and Li, Shi-Ying},
title = {Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202311507}
}
EUVIMED